SCHEMBL1193797

SCHEMBL1193797

O=C(NCCCCO)C1Cc2ccccc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.50
GBA1 P04062 1/20 0.49
MAPT P10636 1/20 0.49
NPY5R Q15761 2/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HDAC3 O15379 2/20 0.43
HDAC4 P56524 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC7 Q8WUI4 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HDAC9 Q9UKV0 2/20 0.43
HDAC5 Q9UQL6 2/20 0.43
DRD3 P35462 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6359841 0.84 PKM (0.53) NAMPTMAPTMEN1KMT2AKDM4E
SCHEMBL1193938 0.81 NAMPT (0.45) NAMPTGBA1NPY5RMEN1KMT2A
SCHEMBL5956886 0.81 HDAC1 (0.66) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6360425 0.80 CHRNB2 (0.46) NAMPTMAPTKDM4EDRD3P2RX7
SCHEMBL1193739 0.78 MAPT (0.61) NAMPTMAPTMEN1KMT2AKDM4E
SCHEMBL22872976 0.76 TP53 (0.45) NPY5RALDH1A1P2RX7MTNR1AMTNR1B
SCHEMBL8672028 0.76 TP53 (0.48) NPY5RALDH1A1P2RX7MTNR1AMTNR1B
SCHEMBL22170856 0.76 NPY5R (0.61) NAMPTGBA1NPY5RP2RX7MTNR1A
SCHEMBL17551505 0.75 NPY5R (0.59) NAMPTGBA1NPY5RP2RX7MTNR1A
SCHEMBL22456651 0.75 TP53 (0.60) ALDH1A1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2220060-B1 TETRAHYDROBENZOTHIAZOLE DERIVATIVES MOTAC NEUROSCIENCE LTD (GB) 2016-09-14 EP disclosed
US-8389555-B2 Medicaments MOTAC NEUROSCIENCE LIMITED (GB) 2013-03-05 US disclosed
US-20110046153-A1 Medicaments MOTAC NEUROSCIENCE LIMITED (GB) 2011-02-24 US disclosed
EP-2220060-A1 MEDICAMENTS Motac Neuroscience Limited (GB) 2010-08-25 EP disclosed
WO-2009056805-A1 MEDICAMENTS MOTAC NEUROSCIENCE LIMITED (GB) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046153-A1 Medicaments MTNR1A, SIGMAR1, OPRK1 NAMPT 4077/4885GBA1 384/4885MAPT 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.